Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/19/2015
Clinical Research Institute of Southern Oregon, PC
mi
from
Medford, OR
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/19/2015
Clinical Research Institute of Southern Oregon, PC
mi
from
Medford, OR
Click here to add this to my saved trials
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/19/2015
Spartanburg Medical Research
mi
from
Spartanburg, SC
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/19/2015
Spartanburg Medical Research
mi
from
Spartanburg, SC
Click here to add this to my saved trials
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/19/2015
Pulmonary Consultants, Pllc
mi
from
Tacoma, WA
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/19/2015
Pulmonary Consultants, Pllc
mi
from
Tacoma, WA
Click here to add this to my saved trials
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/19/2015
Centro de Investigaciones Médicas
mi
from
Florencío Varela,
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/19/2015
Centro de Investigaciones Médicas
mi
from
Florencío Varela,
Click here to add this to my saved trials
Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1
Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence
Status: Enrolling
Updated:  10/21/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1
Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence
Status: Enrolling
Updated: 10/21/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents
Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents
Status: Enrolling
Updated:  10/22/2015
Penn State Hershey Medical Center
mi
from
Hershey, PA
Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents
Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents
Status: Enrolling
Updated: 10/22/2015
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
205.452.01195 Boehringer Ingelheim Investigational Site
mi
from
Panama City, FL
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
205.452.01195 Boehringer Ingelheim Investigational Site
mi
from
Panama City, FL
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
205.452.01270 Boehringer Ingelheim Investigational Site
mi
from
Ann Arbor, MI
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
205.452.01270 Boehringer Ingelheim Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
205.440.1020 Boehringer Ingelheim Investigational Site
mi
from
Livonia, MI
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
205.440.1020 Boehringer Ingelheim Investigational Site
mi
from
Livonia, MI
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Cincinnati, OH
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
1222.52.02029 Boehringer Ingelheim Investigational Site
mi
from
Columbia, OH
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
1222.52.02029 Boehringer Ingelheim Investigational Site
mi
from
Columbia, OH
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
1237.25.10511 Boehringer Ingelheim Investigational Site
mi
from
Dublin, OH
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
1237.25.10511 Boehringer Ingelheim Investigational Site
mi
from
Dublin, OH
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
1268.17.01031 Boehringer Ingelheim Investigational Site
mi
from
Easley, SC
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
1268.17.01031 Boehringer Ingelheim Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
205.477.001002 Boehringer Ingelheim Investigational Site
mi
from
Rock Hill, SC
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
205.477.001002 Boehringer Ingelheim Investigational Site
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
1268.17.01048 Boehringer Ingelheim Investigational Site
mi
from
Killeen, TX
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
1268.17.01048 Boehringer Ingelheim Investigational Site
mi
from
Killeen, TX
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  10/23/2015
1237.25.32004 Boehringer Ingelheim Investigational Site
mi
from
Brussels,
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 10/23/2015
1237.25.32004 Boehringer Ingelheim Investigational Site
mi
from
Brussels,
Click here to add this to my saved trials
High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome
Randomized Control Trial: Heated Humidity High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome in Extreme Low Birth Infants in Immediate Post Extubation Period
Status: Enrolling
Updated:  10/25/2015
Akron Children's Hospital
mi
from
Akron, OH
High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome
Randomized Control Trial: Heated Humidity High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome in Extreme Low Birth Infants in Immediate Post Extubation Period
Status: Enrolling
Updated: 10/25/2015
Akron Children's Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
A Non-interventional Observational Study of Infectious Complications in Cancer Patients
Status: Enrolling
Updated:  10/26/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
A Non-interventional Observational Study of Infectious Complications in Cancer Patients
Status: Enrolling
Updated: 10/26/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Laparoscopic Adjustable Gastric Banding (LAGB) as a Treatment for Morbid Obesity in Adolescents
LAGB Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents
Status: Enrolling
Updated:  10/27/2015
Morgan Stanley Children's Hospital of NY Presbyterian
mi
from
New York, NY
Laparoscopic Adjustable Gastric Banding (LAGB) as a Treatment for Morbid Obesity in Adolescents
LAGB Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents
Status: Enrolling
Updated: 10/27/2015
Morgan Stanley Children's Hospital of NY Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
MBCCOP - University of Illinois at Chicago
mi
from
Chicago, IL
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
MBCCOP - University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Central Illinois
mi
from
Decatur, IL
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Evanston
mi
from
Evanston, IL
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Evanston
mi
from
Evanston, IL
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Wichita
mi
from
Wichita, KA
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Kalamazoo
mi
from
Kalamazoo, MI
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Kalamazoo
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Hematology-Oncology Associates of Central New York
mi
from
East Syracuse, NY
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Hematology-Oncology Associates of Central New York
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Dayton
mi
from
Dayton, OH
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Greenville
mi
from
Greenville, SC
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Northwest
mi
from
Tacoma, WA
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated:  10/27/2015
CCOP - Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Buspirone in Reducing Shortness of Breath in Patients With Cancer
Status: Enrolling
Updated: 10/27/2015
CCOP - Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Click here to add this to my saved trials
Inferior Turbinate Reduction in Pediatric Population Failing Tonsillectomy and Adenoidectomy for Sleep Disordered Breathing
Inferior Turbinate Reduction in Pediatric Population Failing Tonsillectomy and Adenoidectomy for Sleep Disordered Breathing (Randomized, Prospective, Controlled Study)
Status: Enrolling
Updated:  10/28/2015
University Hospitals and Clinics
mi
from
Columbia, MO
Inferior Turbinate Reduction in Pediatric Population Failing Tonsillectomy and Adenoidectomy for Sleep Disordered Breathing
Inferior Turbinate Reduction in Pediatric Population Failing Tonsillectomy and Adenoidectomy for Sleep Disordered Breathing (Randomized, Prospective, Controlled Study)
Status: Enrolling
Updated: 10/28/2015
University Hospitals and Clinics
mi
from
Columbia, MO
Click here to add this to my saved trials
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2a, Randomized, Open-Label, 2-Way Crossover Study To Determine The Pharmacokinetics, Safety, And Tolerability Of Aclidinium/Formoterol 400/12 µg Fixed Dose Combination Via Almirall Inhaler And Formoterol 12 µg Via Foradil® Aerolizer® In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/28/2015
Forest Investigative Site 1121
mi
from
Spartanburg, SC
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2a, Randomized, Open-Label, 2-Way Crossover Study To Determine The Pharmacokinetics, Safety, And Tolerability Of Aclidinium/Formoterol 400/12 µg Fixed Dose Combination Via Almirall Inhaler And Formoterol 12 µg Via Foradil® Aerolizer® In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/28/2015
Forest Investigative Site 1121
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)
Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)
Status: Enrolling
Updated:  10/29/2015
University Medical Center Hospital
mi
from
El Paso, TX
Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)
Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)
Status: Enrolling
Updated: 10/29/2015
University Medical Center Hospital
mi
from
El Paso, TX
Click here to add this to my saved trials
ICS/LABA Adherence and COPD Exacerbation
Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy
Status: Enrolling
Updated:  10/29/2015
Research Facility
mi
from
Wilmington, DE
ICS/LABA Adherence and COPD Exacerbation
Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy
Status: Enrolling
Updated: 10/29/2015
Research Facility
mi
from
Wilmington, DE
Click here to add this to my saved trials
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Group, 20-week Safety, Tolerability, And Efficacy Study Of Pd 0360324 In Adult Subjects With Chronic Pulmonary Sarcoidosis
Status: Enrolling
Updated:  10/30/2015
Drug Shipment Address- Mount Sinai School of Medicine
mi
from
New York, NY
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Group, 20-week Safety, Tolerability, And Efficacy Study Of Pd 0360324 In Adult Subjects With Chronic Pulmonary Sarcoidosis
Status: Enrolling
Updated: 10/30/2015
Drug Shipment Address- Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials